Association between glycolysis and mitochondrial dysfunction and its potential value in liver diseases

Gengjie YAN; Yong LIN; Huiji SU; Hanxiao CHEN; Shaoqun BAN; Ailing WEI; Dewen MAO; Fuli LONG

doi:10.3969/j.issn.1001-5256.2022.08.042

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1931-1936

PDF( 2522 KB)

Association between glycolysis and mitochondrial dysfunction and its potential value in liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.08.042

1.
Graduate School of Guangxi University of Chinese Medicine, Nanning 530200, China
2.
Second Ward of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

National Natural Science Foundation of China (81960841);

National Science and Technology Major Project (2018ZX10725505-001-011);

Guangxi Science and Technology Project (2020GXNSFAA297098);

Guangxi University of Traditional Chinese Medicine Graduate Innovation Project (YCXJ2021034)

More Information

Corresponding author: LONG Fuli, longfuli005@163.com(ORCID: 0000-0003-1196-2697)
Received Date: 2022-04-18
Accepted Date: 2022-05-29
Published Date: 2022-08-20

Abstract

Abstract

Glycolysis plays an important role in the development and progression of liver diseases and shows varying degrees of enhancement in different liver diseases, and it is closely associated with mitochondrial dysfunction (oxidative phosphorylation deficiency and reactive oxygen species production), which helps to fill energy production deficiency caused by impaired oxidative phosphorylation. Therefore, it might be possible to search for potential new therapies for liver diseases through targeted regulation of the key factors in aerobic glycolysis, such as hexokinase 2, pyruvate kinase M2, and other regulatory pathways. From the perspective of the association between glycolysis and liver diseases, this article elaborates on the therapeutic significance and potential value of glycolysis in liver diseases, in order to provide new ideas for the diagnosis and treatment of liver diseases.
- Liver Diseases,
- Glycolysis,
- Mitochondria

FullText(HTML)

References(45)

References

[1]	AUGER C, ALHASAWI A, CONTAVADOO M, et al. Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders[J]. Front Cell Dev Biol, 2015, 3: 40. DOI: 10.3389/fcell.2015.00040.
[2]	WALLACE DC, FAN W, PROCACCIO V. Mitochondrial energetics and therapeutics[J]. Annu Rev Pathol, 2010, 5: 297-348. DOI: 10.1146/annurev.pathol.4.110807.092314.
[3]	NISHIKAWA T, BELLANCE N, DAMM A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease[J]. J Hepatol, 2014, 60(6): 1203-1211. DOI: 10.1016/j.jhep.2014.02.014.
[4]	GO Y, JEONG JY, JEOUNG NH, et al. Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis[J]. Diabetes, 2016, 65(10): 2876-2887. DOI: 10.2337/db16-0223.
[5]	ZHANG M, ZHAO Y, LI Z, et al. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis[J]. Biochem Biophys Res Commun, 2018, 495(1): 582-586. DOI: 10.1016/j.bbrc.2017.11.054.
[6]	SHIRAI T, NAZAREWICZ RR, WALLIS BB, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease[J]. J Exp Med, 2016, 213(3): 337-354. DOI: 10.1084/jem.20150900.
[7]	MIDDLETON P, VERGIS N. Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211031394. DOI: 10.1177/17562848211031394.
[8]	GABBIA D, CANNELLA L, DE MARTIN S. The role of oxidative stress in NAFLD-NASH-HCC transition-focus on NADPH oxidases[J]. Biomedicines, 2021, 9(6): 687. DOI: 10.3390/biomedicines9060687.
[9]	LEE N, CARELLA MA, PAPA S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer[J]. Front Cell Dev Biol, 2018, 6: 138. DOI: 10.3389/fcell.2018.00138.
[10]	LI S, LI J, DAI W, et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death[J]. Br J Cancer, 2017, 117(10): 1518-1528. DOI: 10.1038/bjc.2017.323.
[11]	YE JH, CHAO J, CHANG ML, et al. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation[J]. Sci Rep, 2016, 6: 33102. DOI: 10.1038/srep33102.
[12]	SHANG RZ, QU SB, WANG DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects[J]. World J Gastroenterol, 2016, 22(45): 9933-9943. DOI: 10.3748/wjg.v22.i45.9933.
[13]	LUNT SY, VANDER HEIDEN MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation[J]. Annu Rev Cell Dev Biol, 2011, 27: 441-464. DOI: 10.1146/annurev-cellbio-092910-154237.
[14]	SCIACOVELLI M, GAUDE E, HILVO M, et al. The metabolic alterations of cancer cells[J]. Methods Enzymol, 2014, 542: 1-23. DOI: 10.1016/B978-0-12-416618-9.00001-7.
[15]	LIU J, JIANG S, ZHAO Y, et al. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions[J]. J Pathol, 2018, 246(3): 277-288. DOI: 10.1002/path.5131.
[16]	KORS L, RAMPANELLI E, STOKMAN G, et al. Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1883-1895. DOI: 10.1016/j.bbadis.2018.03.003.
[17]	SHANNON CE, RAGAVAN M, PALAVICINI JP, et al. Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease[J]. Mol Metab, 2021, 45: 101154. DOI: 10.1016/j.molmet.2020.101154.
[18]	WANG T, CHEN K, YAO W, et al. Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance[J]. J Hepatol, 2021, 74(5): 1038-1052. DOI: 10.1016/j.jhep.2020.11.028.
[19]	SHIMADA K, CROTHER TR, KARLIN J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis[J]. Immunity, 2012, 36(3): 401-414. DOI: 10.1016/j.immuni.2012.01.009.
[20]	XU F, GUO M, HUANG W, et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH[J]. Redox Biol, 2020, 36: 101634. DOI: 10.1016/j.redox.2020.101634.
[21]	SUN M, KISSELEVA T. Reversibility of liver fibrosis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(Suppl 1): S60-S63. DOI: 10.1016/j.clinre.2015.06.015.
[22]	WANG F, JIA Y, LI M, et al. Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells[J]. Cell Commun Signal, 2019, 17(1): 11. DOI: 10.1186/s12964-019-0324-8.
[23]	WAN L, XIA T, DU Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells[J]. FASEB J, 2019, 33(7): 8530-8542. DOI: 10.1096/fj.201802675R.
[24]	HUANG T, LI YQ, ZHOU MY, et al. Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway[J]. World J Gastroenterol, 2022, 28(1): 123-139. DOI: 10.3748/wjg.v28.i1.123.
[25]	RAO J, WANG H, NI M, et al. FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2[J]. Gut, 2022. DOI: 10.1136/gutjnl-2021-325150.[Online ahead of print]
[26]	ZHENG D, JIANG Y, QU C, et al. Pyruvate kinase M2 tetramerization protects against hepatic stellate cell activation and liver fibrosis[J]. Am J Pathol, 2020, 190(11): 2267-2281. DOI: 10.1016/j.ajpath.2020.08.002.
[27]	ZHOU MY, CHENG ML, HUANG T, et al. Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and noncanonical pathways in hepatic stellate cells[J]. World J Gastroenterol, 2021, 27(40): 6908-6926. DOI: 10.3748/wjg.v27.i40.6908.
[28]	BAN D, HUA S, ZHANG W, et al. Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2[J]. Cell Mol Biol Lett, 2019, 24: 52. DOI: 10.1186/s11658-019-0179-4.
[29]	MATHUPALA SP, KO YH, PEDERSEN PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy[J]. Semin Cancer Biol, 2009, 19(1): 17-24. DOI: 10.1016/j.semcancer.2008.11.006.
[30]	VAUPEL P, SCHMIDBERGER H, MAYER A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression[J]. Int J Radiat Biol, 2019, 95(7): 912-919. DOI: 10.1080/09553002.2019.1589653.
[31]	DEWAAL D, NOGUEIRA V, TERRY AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J]. Nat Commun, 2018, 9(1): 446. DOI: 10.1038/s41467-017-02733-4.
[32]	MATHUPALA SP, KO YH, PEDERSEN PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy[J]. Semin Cancer Biol, 2009, 19(1): 17-24. DOI: 10.1016/j.semcancer.2008.11.006.
[33]	KANAI S, SHIMADA T, NARITA T, et al. Phosphofructokinase-1 subunit composition and activity in the skeletal muscle, liver, and brain of dogs[J]. J Vet Med Sci, 2019, 81(5): 712-716. DOI: 10.1292/jvms.19-0049.
[34]	BARTRONS R, RODRÍGUEZ-GARCÍA A, SIMON-MOLAS H, et al. The potential utility of PFKFB3 as a therapeutic target[J]. Expert Opin Ther Targets, 2018, 22(8): 659-674. DOI: 10.1080/14728222.2018.1498082.
[35]	LI S, DAI W, MO W, et al. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(12): 2571-2584. DOI: 10.1002/ijc.31022.
[36]	van NIEKERK G, ENGELBRECHT AM. Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target[J]. Cell Oncol (Dordr), 2018, 41(4): 343-351. DOI: 10.1007/s13402-018-0383-7.
[37]	AZOITEI N, BECHER A, STEINESTEL K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation[J]. Mol Cancer, 2016, 15: 3. DOI: 10.1186/s12943-015-0490-2.
[38]	LUO W, HU H, CHANG R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell, 2011, 145(5): 732-744. DOI: 10.1016/j.cell.2011.03.054.
[39]	WONG N, OJO D, YAN J, et al. PKM2 contributes to cancer metabolism[J]. Cancer Lett, 2015, 356(2 Pt A): 184-191. DOI: 10.1016/j.canlet.2014.01.031.
[40]	FENG J, WU L, JI J, et al. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 204. DOI: 10.1186/s13046-019-1194-z.
[41]	LIU B, JIN J, ZHANG Z, et al. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway[J]. Biochem Cell Biol, 2019, 97(4): 397-405. DOI: 10.1139/bcb-2018-0310.
[42]	LING Y, YAN GJ, FENG F, et al. Association between cholesterol and liver regeneration and its significance and potential value in clinical treatment of liver failure[J]. J Clin Hepatol, 2022, 38(3): 708-713. DOI: 10.3969/j.issn.1001-5256.2022.03.044. 林镛, 颜耿杰, 冯逢, 等. 胆固醇与肝再生关系及其在肝衰竭治疗中的意义和潜在价值[J]. 临床肝胆病杂志, 2022, 38(3): 708-713. DOI: 10.3969/j.issn.1001-5256.2022.03.044.
[43]	WANG Y, LI X, CHEN Q, et al. Histone deacetylase 6 regulates the activation of M1 macrophages by the glycolytic pathway during acute liver failure[J]. J Inflamm Res, 2021, 14: 1473-1485. DOI: 10.2147/JIR.S302391.
[44]	WANG XF, SHI QL, WANG MG, et al. Experimental study on effect of Jiedu Huayu granules on hepatic mitochondrial permeability transition in rats with acute liver failure[J]. Liaoning J Tradit Chin Med, 2017, 44(10): 2186-2189. DOI: 10.13192/j.issn.1000-1719.2017.10.056. 王秀峰, 石清兰, 王明刚, 等. 解毒化瘀颗粒抑制急性肝衰竭大鼠肝线粒体通透性转换的实验研究[J]. 辽宁中医杂志, 2017, 44(10): 2186-2189. DOI: 10.13192/j.issn.1000-1719.2017.10.056.
[45]	ZHANG RZ, MAO DW, SUN KW, et al. Mechanism of action of Jieduhuayu granules for remission of oxidative stress in hepatocytes[J]. Chin J Hepatol, 2021, 29(12): 1188-1193. DOI: 10.3760/cma.j.cn501113-20210721-00349. 张荣臻, 毛德文, 孙克伟, 等. 解毒化瘀颗粒缓解肝细胞氧化应激的作用机制[J]. 中华肝脏病杂志, 2021, 29(12): 1188-1193. DOI: 10.3760/cma.j.cn501113-20210721-00349.

Relative Articles

[1]	Qinwen TAN, Jingjing HUANG, Ruixi ZHONG, Yuanqin DU, Jian XU, Jinli NONG, Yujiao PENG. Effect of Biejia Decoction Pill on aerobic glycolysis in hepatocellular carcinoma by regulating the protein kinase B/mammalian target of rapamycin signaling pathway[J]. Journal of Clinical Hepatology, 2025, 41(2): 300-306. doi: 10.12449/JCH250216
[2]	Haishan SHEN, Shuo WANG, Gong FENG. Role of dynamin-related protein 1 in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2025, 41(1): 159-163. doi: 10.12449/JCH250124
[3]	Xingtong LI, Taicheng ZHOU. Molecular mechanisms of the interaction between hepatitis B virus infection and mitochondrial homeostasis[J]. Journal of Clinical Hepatology, 2025, 41(2): 343-348. doi: 10.12449/JCH250222
[4]	Tianhui LIU. Role of organelle interaction in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 181-187. doi: 10.3969/j.issn.1001-5256.2023.01.028
[5]	Yanhong BAO, Qiang WANG, Wenlong ZHANG, Na GE, Nan LI, Jun SU, Kexin LI. Ursolic acid in Hippophae rhamnoides L. inhibits hepatocyte apoptosis in rats with alcoholic liver disease by regulating mitochondria-cytochrome c[J]. Journal of Clinical Hepatology, 2023, 39(7): 1617-1626. doi: 10.3969/j.issn.1001-5256.2023.07.016
[6]	Mingyin MAN, Nana LI, Yue BU, Kaijiang YU. Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis[J]. Journal of Clinical Hepatology, 2022, 38(2): 392-396. doi: 10.3969/j.issn.1001-5256.2022.02.025
[7]	Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Association between mitochondrial dysfunction and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1436-1439. doi: 10.3969/j.issn.1001-5256.2022.06.045
[9]	Weichun XIAO, Wei AN. Role of mitochondrial injury in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1515-1521. doi: 10.3969/j.issn.1001-5256.2021.07.005
[10]	Tianying CAI, Meizhou HUANG, Hao CHEN, Baolin QIAN, Wenguang FU. Mechanism of action of mitochondrial disorders in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1953-1956. doi: 10.3969/j.issn.1001-5256.2021.08.045
[11]	Wei HaiLiang, Si MingMing, Guo Hui, Li JingTao, Li Qian, Yan ShuGuang, Ju Di. Association between mitochondria and hepatocellular injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 687-689. doi: 10.3969/j.issn.1001-5256.2020.03.048
[12]	Xu ZiXin, Luo ShengZheng, Xu MingYi. Mechanism of mitochondrial dysfunction in the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2353-2355. doi: 10.3969/j.issn.1001-5256.2020.10.042
[14]	Zhou ZhenHua, Wang LingTai, Gao YueQiu. Role of hepatocyte mitophagy in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2809-2811. doi: 10.3969/j.issn.1001-5256.2019.12.036
[15]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[16]	Duan YiFei, Zhao QingXi, Jing Xue. Effect of long non-coding RNAs on glycolytic pathway in primary liver cancer and related mechanisms[J]. Journal of Clinical Hepatology, 2019, 35(6): 1374-1376. doi: 10.3969/j.issn.1001-5256.2019.06.043
[17]	Zhang Qian, Han Tao. Research progress in advanced oxidation protein products in liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(8): 581-584. doi: 10.3969/j.issn.1001-5256.2013.08.007
[18]	Gao YanHang. Summary of symposium of translational medicine on liver disease[J]. Journal of Clinical Hepatology, 2011, 27(9): 1008-1009.
[19]	Bai WenYuan, Liu Na. Prevention and thorough consideration of drug induced liver injury[J]. Journal of Clinical Hepatology, 2011, 27(3): 245-247.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	林镛，颜耿杰，张衎，舒发明，王明刚，刘美燕，曹音，龙富立，毛德文. 乳酸与免疫的调节关系及其在肝衰竭诊疗中的价值. 胃肠病学和肝病学杂志. 2024(08): 1107-1112 .
2.	常婧，程秋骆，张丽霞，王芊沣，华鹏，黄以蓉，崔翔. 基于肝脏能量代谢途径变化探讨健脾化浊消脂方对代谢相关脂肪性肝病大鼠的干预机制. 中南药学. 2024(10): 2650-2655 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (1736) PDF downloads(170)

Association between glycolysis and mitochondrial dysfunction and its potential value in liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.08.042